In addition, the external validation cohort comprised 46 breast cancer patients (18 were HER2‐negative, 14 were HER2‐low, and 14 were HER2‐positive cases), and the mean age of this cohort was 55.3 ± 7.2 years. Here, ERBB2 is linked to breast carcinoma.